Hyperleptinemia Exacerbates High-Fat Diet-Mediated Atrial Fibrosis and Fibrillation

Journal of Cardiovascular Electrophysiology

Volumn 28, Issue 6, 2017, Pages 702-710

  Fukui, Akira ^a   Ikebe Ebata, Yuki ^a   Kondo, Hidekazu ^a   Saito, Shotaro ^a   Aoki, Kohei ^a   Fukunaga, Naoya ^a   Shinohara, Tetsuji ^a   Masaki, Takayuki ^a   Teshima, Yasushi ^a   Takahashi, Naohiko ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

atrial fibrillation; atrial fibrosis; inflammation; leptin; obesity

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; GLUCOSE; HYDROXYPROLINE; INSULIN; LEPTIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; ACTIN; ALPHA-SMOOTH MUSCLE ACTIN, MOUSE; BIOLOGICAL MARKER; CCL2 PROTEIN, MOUSE; COLLAGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATRIAL FIBRILLATION; ATRIAL FIBROSIS; BLOOD CHEMISTRY; BODY WEIGHT; CONTROLLED STUDY; DISEASE EXACERBATION; FIBROSIS; GLUCOSE BLOOD LEVEL; HEART ELECTROPHYSIOLOGY; HEART LEFT ATRIUM; HEART PERFUSION; HEART TISSUE; HEMODYNAMICS; HISTOLOGY; HYPERLEPTINEMIA; INSULIN BLOOD LEVEL; ISOLATED HEART; LIPID DIET; MALE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; UPREGULATION; ANIMAL; BLOOD; C57BL MOUSE; COMPLICATION; DISEASE MODEL; GENETICS; HEART ATRIUM; HEART PACING; HEART RATE; METABOLISM; MOUSE MUTANT; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; TIME FACTOR;

ACTINS; ANIMALS; ATRIAL FIBRILLATION; BIOMARKERS; CARDIAC PACING, ARTIFICIAL; CHEMOKINE CCL2; COLLAGEN; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FIBROSIS; HEART ATRIA; HEART RATE; HYDROXYPROLINE; ISOLATED HEART PREPARATION; LEPTIN; MALE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; RNA, MESSENGER; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 85018943854     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/jce.13200     Document Type: Article

References (35)

1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D: Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998;98:946-952.
2. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375.
3. Wang TJ, Parise H, Levy D, D'Agostino RB Sr, Wolf PA, Vasan RS, Benjamin EJ: Obesity and the risk of new-onset atrial fibrillation. JAMA 2004;292:2471-2477.
4. Nalliah CJ, Sanders P, Kottkamp H, Kalman JM: The role of obesity in atrial fibrillation. Eur Heart J 2016;37:1565-1572.
5. Watanabe H, Tanabe N, Watanabe T, Darbar D, Roden DM, Sasaki S, Aizawa Y: Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation 2008;117:1255-1260.
6. Abed HS, Samuel CS, Lau DH, Kelly DJ, Royce SG, Alasady M, Mahajan R, Kuklik P, Zhang Y, Brooks AG, Nelson AJ, Worthley SG, Abhayaratna WP, Kalman JM, Wittert GA, Sanders P: Obesity results in progressive atrial structural and electrical remodeling: Implications for atrial fibrillation. Heart Rhythm 2013;10:90-100.
7. Yamaguchi T, Tsuchiya T, Nakahara S, Fukui A, Nagamoto Y, Murotani K, Eshima K, Takahashi N: Efficacy of left atrial voltage-based catheter ablation of persistent atrial fibrillation. J Cardiovasc Electrophysiol 2016;27:1055-1063.
8. Dinov B, Kosiuk J, Kircher S, Bollmann A, Acou WJ, Arya A, Hindricks G, Rolf S: Impact of metabolic syndrome on left atrial electroanatomical remodeling and outcomes after radiofrequency ablation of nonvalvular atrial fibrillation. Circ Arrhythm Electrophysiol 2014;7:483-489.
9. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-432.
10. Gautron L, Elmquist JK: Sixteen years and counting: an update on leptin in energy balance. J Clin Invest 2011;121:2087-2093.
11. Ikejima K, Honda H, Yoshikawa M, Hirose M, Kitamura T, Takei Y, Sato N: Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 2001;34:288-297.
12. Tanaka M, Suganami T, Sugita S, Shimoda Y, Kasahara M, Aoe S, Takeya M, Takeda S, Kamei Y, Ogawa Y: Role of central leptin signaling in renal macrophage infiltration. Endocr J 2010;57:61-72.
13. Rajapurohitam V, Gan XT, Kirshenbaum LA, Karmazyn M: The obesity associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ Res 2003;93:277-279.
14. Yang R, Barouch LA: Leptin signaling and obesity: cardiovascular consequences. Circ Res 2007;101:545-559.
15. Bobbert P, Jenke A, Bobbert T, Kühl U, Rauch U, Lassner D, Scheibenbogen C, Poller W, Schultheiss HP, Skurk C: High leptin and resistin expression in chronic heart failure: Adverse outcome in patients with dilated and inflammatory cardiomyopathy. Eur J Heart Fail 2012;14:1265-1275.
16. Fukui A, Takahashi N, Nakada C, Masaki T, Kume O, Shinohara T, Teshima Y, Hara M, Saikawa T: Role of leptin signaling in the pathogenesis of angiotensin II-mediated atrial fibrosis and fibrillation. Circ Arrhythm Electrophysiol 2013;6:402-409.
17. Saito S, Teshima Y, Fukui A, Kondo H, Nishio S, Nakagawa M, Saikawa T, Takahashi N: Glucose fluctuations increase the incidence of atrial fibrillation in diabetic rats. Cardiovasc Res 2014;104:5-14.
18. Wang MY, Orci L, Ravazzola M, Unger RH: Fat storage in adipocytes requires inactivation of leptin's paracrine activity: Implications for treatment of human obesity. Proc Natl Acad Sci U S A 2005;102:18011-18016.
19. Grassi G, Mark A, Esler M: The sympathetic nervous system alterations in human hypertension. Circ Res 2015;116:976-990.
20. Belin de Chantemèle EJ, Mintz JD, Rainey WE, Stepp DW: Impact of leptin-mediated sympatho-activation on cardiovascular function in obese mice. Hypertension 2011;58:271-279.
21. Rennison JH, McElfresh TA, Chen X, Anand VR, Hoit BD, Hoppel CL, Chandler MP: Prolonged exposure to high dietary lipids is not associated with lipotoxicity in heart failure. J Mol Cell Cardiol 2009;46:883-890.
22. Nattel S, Burstein B, Dobrev D: Atrial remodeling and atrial fibrillation: Mechanisms and implications. Circ Arrhythm Electrophysiol 2008;1:62-73.
23. Takahashi K, Sasano T, Sugiyama K, Kurokawa J, Tamura N, Soejima Y, Sawabe M, Isobe M, Furukawa T: High-fat diet increases vulnerability to atrial arrhythmia by conduction disturbance via miR-27b. J Mol Cell Cardiol 2016;90:38-46.
24. Aromolaran AS, Colecraft HM, Boutjdir M: High-fat diet-dependent modulation of the delayed rectifier K(+) current in adult guinea pig atrial myocytes. Biochem Biophys Res Commun 2016;474:554-559.
25. Li J, Solus J, Chen Q, Rho YH, Milne G, Stein CM, Darbar D: Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 2010;7:438-444.
26. Saba S, Janczewski AM, Baker LC, Shusterman V, Gursoy EC, Feldman AM, Salama G, McTiernan CF, London B: Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-{alpha}. Am J Physiol Heart Circ Physiol 2005;289:H1456-67.
27. Kume O, Takahashi N, Wakisaka O, Nagano-Torigoe Y, Teshima Y, Nakagawa M, Yufu K, Hara M, Saikawa T, Yoshimatsu H: Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. Heart Rhythm 2011;8:278-285.
28. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA: Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-844.
29. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, Kern PA, Friedman JM: Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995;1:1155-1161.
30. Putnam K, Shoemaker R, Yiannikouris F, Cassis LA: The renin-angiotensin system: A target of and contributor to dyslipidemias,altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol 2012;302:H1219-30.
31. Mazumder PK, O'Neill BT, Roberts MW, Buchanan J, Yun UJ, Cooksey RC, Boudina S, Abel ED: Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 2004;53:2366-2374.
32. Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ, Cooksey RC, Litwin SE, Abel ED: Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005;146:5341-5349.
33. Sloan C, Tuinei J, Nemetz K, Frandsen J, Soto J, Wride N, Sempokuya T, Alegria L, Bugger H, Abel ED: Central leptin signaling is required to normalize myocardial fatty acid oxidation rates in caloric-restricted ob/ob mice. Diabetes 2011;60:1424-1434.
34. Shimizu I, Minamino T, Toko H, Okada S, Ikeda H, Yasuda N, Tateno K, Moriya J, Yokoyama M, Nojima A, Koh GY, Akazawa H, Shiojima I, Kahn CR, Abel ED, Komuro I: Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J Clin Invest 2010;120:1506-1514.
35. Carlyle M, Jones OB, Kuo JJ, Hall JE: Chronic cardiovascular and renal actions of leptin: Role of adrenergic activity. Hypertension 2002;39:4.